Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...
Brickell Biotech Announces 1-For-45 Reverse Stock Split
Common stock will begin trading on a split-adjusted basis on July 5, 2022...
Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update
Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments,...
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...